WO2018038292A1 - Pharmaceutical composition containing cinnamomum camphora extract as active ingredient for the prevention and treatment of neurological diseases - Google Patents

Abstract

The present invention relates to a pharmaceutical composition containing, as an active ingredient, a Cinnamomum camphora extract, for the prevention and treatment of neurological diseases. It was confirmed that when the Cinnamomum camphora extract was prepared and injected into an Alzheimer's-related dementia animal model, the instantaneous spatial perception of the animal model improved and the decline in learning and memory was mitigated, thereby confirming that the Cinnamomum camphora extract could be effectively used in alleviating and treating Alzheimer's-related dementia.

Description

Pharmaceutical composition for the prevention and treatment of neurological diseases containing camphor extract as an active ingredient

The present invention is a camphor tree ( Cinnamomum Camphora ) relates to a pharmaceutical composition for the prevention and treatment of diseases of the nervous system containing the extract as an active ingredient.

As we enter an aging society, there is an increasing interest in aging, as well as related neurological diseases such as diseases, strokes and Alzheimer's dementia. Among various brain diseases, dementia is one of the most widespread cell damage disorders. It is accompanied by degenerative mental disorders, especially memory disorders and loss of judgment. Types of dementia include vascular dementia (20-30%) due to narrowing or occlusion of the blood vessels, Alzheimer's dementia (50%), which is known to be caused by accumulation of beta amyloid protein in the brain, and a combination of these two causes. It can be broadly divided into mixed dementia (15-20%). The most common type of dementia among patients is Alzheimer's dementia, and a recent study reports that by 2050, 1 in 85 people will have the disease, 43% of whom require intensive care (Prabhulkar S, Piatyszek R, et al. J Neurochem., 2012, 122, 374-381).

Alzheimer's dementia is largely classified into hereditary Alzheimer's disease and sporadic Alzheimer's disease. Hereditary Alzheimer's disease accounts for about 5 to 10% of all Alzheimer's dementia patients and affects presenilin 1, amyloid precursor protein, and presenilin 2, which are known as causative genes. Mutations result in 100% Alzheimer's dementia. Sporadic Alzheimer's disease accounts for the majority of Alzheimer's dementia patients and is a risk factor that increases the chances of developing Alzheimer's disease when mutations in apolipoprotein E or Alpha-2 macroglobulin occur. To date, the exact cause of the disease is unknown.

The pathological characteristics of Alzheimer's dementia include senile plaques that accumulate outside the neurons, neurofibrilary tangles that look like tangled threads within the neuronal cell bodies, and neuronal loss. Etc. can be mentioned. This pathological feature is present in all cases of hereditary Alzheimer's disease and sporadic Alzheimer's disease, of which toxic proteins called aggregated amyloid beta peptides have been identified as a major component of senile plaques. Amyloid beta peptides are insoluble peptides consisting of 40 to 42 amino acids resulting from abnormal cleavage of amyloid proproteins, and excessive accumulation of amyloid beta peptides is reported to be common in all cases of hereditary Alzheimer's disease and sporadic Alzheimer's disease. It is considered a major pathogenic material for Alzheimer's disease.

The overall pathogenesis of Alzheimer's dementia is that amyloid proproteins are abnormally cleaved by β-secretase and amyloid beta peptides are produced when mutations of the presenilin 1 and 2 genes occur. Necrosis of cerebral neurons is caused by amyloid beta peptides, which is known to cause Alzheimer's disease.

To date, a wide variety of researches have been conducted on the causes and treatments of dementia, but the cause is insufficient and the development of effective treatments is still insufficient. Although tacrine, rivastigmine, galantamine, donepezil and memantine have been approved by the FDA as treatments for Alzheimer's dementia, currently used dementia treatments are available for treatment. It is not a drug that makes the progress or symptoms, but only to temporarily reduce. Moreover, as neuronal cell death progresses, the effect of the drug decreases, and severe dementia does not work. In addition, most of these are anti-inflammatory drugs and have side effects such as hepatotoxicity and damaging the mucous membranes of the digestive organs, there is a limit that is limited to symptomatic therapy rather than the ultimate cause therapy.

Currently, many pharmaceutical companies are spurring research and development to develop dementia-related drugs, but the economic and social effects of new drug development are enormous, but their development costs are enormous, making them difficult to develop. However, Chinese medicine and natural products contain many unknown ingredients, and our ancestors have long experiences of using a relatively secure safety. Since herbal extracts have been used for the prevention of dementia, oriental medicine has a very high potential in the treatment of neurological diseases, and it is necessary to conduct systematic researches using the same.

Camphor tree ( Cinnamomum camphora ) was designated as Natural Monument No. 162 in Korea and grows in Seogwipo, Jeju Island. Camphor is a plant belonging to the family Lauraceae, with a height of 20 m and a height of 2 m in diameter, free of pests and long life. Mainly dried branches are called camphor, which has been used for medicinal purposes. Camphor, an essential oil, is the main ingredient in camphor. In addition to cineol, α-pinene, 1-camphene, δ-limonene, and saprol (safrol) and α-camphorene are reported to be contained. In Japan, camphor is very valued and treated as a national monopoly like ginseng in our country. In Korea, camphor tree has been used as a cancer drug in the private sector in Jeju Island, but there are few reports on the physiological activity of camphor tree components.

The present inventors tried to develop a treatment for Alzheimer's dementia using herbal medicine or natural products with few side effects, and confirmed that camphor extract showed the effect of improving spatial cognition and improving spatial learning and memory in Alzheimer's dementia animal model. The invention has been completed.

An object of the present invention is a camphor tree ( Cinnamomum Camphora ) to provide a pharmaceutical composition for the prevention and treatment of neurological diseases containing the extract as an active ingredient.

In order to achieve the above object, the present invention is a camphor tree ( Cinnamomum Camphora ) provides a pharmaceutical composition for the prevention and treatment of diseases of the nervous system containing the extract as an active ingredient.

In addition, the present invention provides a health functional food for the prevention and improvement of neurological diseases containing camphor extract as an active ingredient.

Camphor tree of the present invention ( Cinnamomum camphora ) extract has no effect on motor function, improves instantaneous spatial cognition and mitigates learning and memory reduction, thereby making camphor extract useful for improving and treating Alzheimer's dementia. Can be used.

1 is a camphor tree ( Cinnamomum This figure shows the measurement of gait movement in mice after the administration of camphora ) extract:

sham control group that did not induce Alzheimer's dementia model;

negative control: group administered with distilled water after Alzheimer's dementia induction;

positive control: 1 mg / kg of donepezil after Alzheimer's dementia induction;

EXP. 1 (200 mg / kg): group administered with 200 mg / kg camphor extract after Alzheimer's dementia induction; And

EXP. 2 (600 mg / kg): A group of 600 mg / kg camphor extract was administered after Alzheimer's dementia induction.

2 is a diagram showing the measurement of the instantaneous spatial cognition of mice after administration of camphor extract:

sham control group that did not induce Alzheimer's dementia model;

negative control: group administered with distilled water after Alzheimer's dementia induction;

positive control: 1 mg / kg of donepezil after Alzheimer's dementia induction;

EXP. 1 (200 mg / kg): group administered with 200 mg / kg camphor extract after Alzheimer's dementia induction; And

EXP. 2 (600 mg / kg): A group of 600 mg / kg camphor extract was administered after Alzheimer's dementia induction.

Figure 3 is a diagram showing the measurement of learning and memory of mice after administration of camphor extract:

sham control group that did not induce Alzheimer's dementia model;

negative control: group administered with distilled water after Alzheimer's dementia induction;

positive control: 1 mg / kg of donepezil after Alzheimer's dementia induction;

EXP. 1 (200 mg / kg): group administered with 200 mg / kg camphor extract after Alzheimer's dementia induction; And

EXP. 2 (600 mg / kg): A group of 600 mg / kg camphor extract was administered after Alzheimer's dementia induction.

Hereinafter, the present invention will be described in detail.

The present invention is a camphor tree ( Cinnamomum Camphora ) provides a pharmaceutical composition for the prevention and treatment of diseases of the nervous system containing the extract as an active ingredient.

The camphor tree can be used without limitation, such as those grown or commercially available. The camphor tree may be any one of vine stems, branches, roots, stems, leaves, petals and buds of the cognate plant, but is not limited thereto. According to a preferred embodiment of the present invention, the camphor tree leaves or cognate plant Most preferably, the leaves of the plant are used.

In addition, in the extraction, the extraction solvent of camphor extract is preferably water, alcohol or a mixture thereof. The alcohol is preferably C ₁ to C ₂ lower alcohol, it is preferable to use a lower alcohol or ethanol or methanol. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but not always limited thereto. The extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried camphor, and more preferably by adding 4 to 6 times. The extraction temperature is preferably 20 to 100 ° C, more preferably 20 to 40 ° C, and most preferably room temperature, but is not limited thereto. In addition, the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. In addition, the number of extraction is preferably 1 to 5 times, more preferably 3 to 4 repetitions, and most preferably 3 times, but is not limited thereto.

In the above method, the vacuum concentrator is preferably used as a vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.

In addition, the neurological disorders specifically include spinal cord injury, Parkinson's disease, stroke, amyotrophic spinal lateral sclerosis, motor neuron injury, peripheral nerve injury due to trauma, ischemic brain injury, neonatal hypoxic ischemic brain injury, cerebral palsy , Epilepsy, refractory epilepsy, Alzheimer's disease, congenital metabolic neurological disease and traumatic brain injury, and may be any one selected from the group consisting of spinal cord injury, The present invention is not limited thereto and is applicable to all neurological diseases that may occur due to nerve damage.

In a specific embodiment of the present invention, the present inventors pulverized the dried camphor leaf to extract the hot water using water or a mixed solvent of water and alcohol and freeze-dried to obtain a powder X. The obtained camphor extract was administered to Alzheimer's dementia-induced mice, and it was confirmed that there was no problem of motor function and no effect on walking activity (see FIG. 1). In addition, administration of the camphor extract to the Alzheimer's dementia-induced mice to perform the Y-shaped maze type test, Morris water maze test, it was confirmed that the instantaneous spatial cognition is improved (see Fig. 2), the learning and memory reduction is alleviated (Fig. 3). Therefore, the camphor extract of the present invention can be usefully used for improving and treating Alzheimer's dementia.

The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" of the invention is meant to exhibit properties that are not toxic to cells or humans exposed to the composition. Compositions comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used. The carrier, excipient and diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinyl pyrrolidone, saline, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol and liquid paraffin, but There is no limitation, and any conventional carrier, excipient or diluent can be used. The components may be added independently or in combination to the camphor extract which is the active ingredient.

Solid preparations for oral administration may include tablet pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose or lactose in one or more compounds. (lactose), gelatin can be prepared by mixing. In addition to the simple excipients, lubricants such as magnesium stearate, talc and the like can also be used. Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As a suppository base, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

In addition, the pharmaceutical composition of the present invention is a group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories It can have any one formulation selected from.

The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount. There is no particular restriction on the dosage, and it may vary depending on body absorption, weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of disease. The pharmaceutical compositions of the present invention may be prepared in consideration of the effective amount range, and the unit dosage form formulated in this way may be formulated using a specialized dosage method according to the judgment of a professional who monitors or observes the administration of the drug as required and the needs of the individual. It can be used or administered several times at regular time intervals. Preferably the pharmaceutical composition of the present invention may be administered based on the amount of camphor extract 0.5 to 5000 mg / kg, preferably 50 to 500 mg / kg, more preferably 50 mg / kg per day The administration may be administered once a day, or may be divided several times.

The present invention is a camphor tree ( Cinnamomum camphora ) Provides a health functional food for the prevention and improvement of neurological diseases containing the extract as an active ingredient.

The camphor tree can be used without limitation, such as those grown or commercially available. The camphor tree may be any one of vine stems, branches, roots, stems, leaves, petals and buds of the cognate plant, but is not limited thereto. According to a preferred embodiment of the present invention, the camphor tree leaves or cognate plant Most preferably, the leaves of the plant are used.

In addition, in the extraction, the extraction solvent of camphor extract is preferably water, alcohol or a mixture thereof. The alcohol is preferably C ₁ to C ₂ lower alcohol, it is preferable to use a lower alcohol or ethanol or methanol. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but not always limited thereto. The extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried camphor, and more preferably by adding 4 to 6 times. The extraction temperature is preferably 20 to 100 ° C, more preferably 20 to 40 ° C, and most preferably room temperature, but is not limited thereto. In addition, the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto. In addition, the number of extraction is preferably 1 to 5 times, more preferably 3 to 4 repetitions, and most preferably 3 times, but is not limited thereto.

In the above method, the vacuum concentrator is preferably used as a vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.

In addition, the neurological disorders specifically include spinal cord injury, Parkinson's disease, stroke, amyotrophic spinal lateral sclerosis, motor neuron injury, peripheral nerve injury due to trauma, ischemic brain injury, neonatal hypoxic ischemic brain injury, cerebral palsy , Epilepsy, refractory epilepsy, Alzheimer's disease, congenital metabolic neurological disease, and traumatic brain injury may be one selected from the group consisting of, more specifically, spinal cord injury, but The present invention is not limited thereto and is applicable to all neurological diseases that may occur due to nerve damage.

In a specific embodiment of the present invention, the present inventors pulverized the dried camphor leaf to extract the hot water using water or a mixed solvent of water and alcohol and freeze-dried to obtain a powder X. The obtained camphor extract was administered to Alzheimer's dementia-induced mice, and it was confirmed that there was no problem of motor function and no effect on walking activity (see FIG. 1). In addition, administration of the camphor extract to the Alzheimer's dementia-induced mice to perform the Y-shaped maze type test, Morris water maze test, it was confirmed that the instantaneous spatial cognition is improved (see Fig. 2), the learning and memory reduction is alleviated (Fig. 3). Therefore, the camphor extract of the present invention can be usefully used for improving and treating Alzheimer's dementia.

The health functional food of the present invention may contain various flavors or natural carbohydrates as additional ingredients. The above-mentioned natural carbohydrates are sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin, aspartame, and the like can be used. The ratio of the natural carbohydrate can be selected from 0.01 to 0.04 parts by weight, specifically about 0.02 to 0.03 parts by weight per 100 parts by weight of the health functional food of the present invention.

In addition to the above, the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. These components can be used independently or in combination. The ratio of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.

Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.

However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

< Example  1> Preparation of Camphor Extract

<1-1> Camphor Extract Preparation Using Water as a Solvent

Cinnamomum harvested from Yeosu, Jeollanam-do camphora ) leaves were dried and used in the experiment. 100 g of the pulverized camphor leaf was added to 1 L of distilled water, stirred, and then refluxed at a temperature of 90 to 95 ° C. for 3 hours. Thereafter, the filtrate was separated, and the extract was concentrated under reduced pressure at 55 to 65 ° C., and then freeze-dried to obtain a herbal composition powder × 21.2 g.

<1-2> Camphor Extract Preparation Using Mixed Solvents of Water and Alcohol

3 L of 30% ethyl alcohol was added to 600 g of the crushed camphor tree leaves in the same manner as in <Example 1-1>, followed by extraction under reflux for 3 hours at a temperature of 80 to 90 ° C. Thereafter, the filtrate was separated, and the extract was concentrated under reduced pressure at 55 to 65 ° C., and then freeze-dried to obtain X 135 g of the herbal composition powder.

< Experimental Example  1> Check the effect of camphor extract on walking activity

<1-1> Alzheimer's Dementia Animal Model

In order to confirm the effect on the nervous system disease treatment and prevention of camphor leaf extract of the present invention, the production of amyloid beta peptide (peptide Amylodi beta1- ₄₂₎ that the animal model ₍₄₂ Amylodi beta1- infused mouse model) induced dementia through the injection It was.

Specifically, C57BL / 6 mice were anesthetized with anesthetized mixture of zoletil and rompun 2: 1, and then the hippocampal CA1 region of the brain (coordinates: -2.3 mm anterior / posterior, 1.8 mm medial). Alzheimer's dementia animal model was prepared by injecting amyloid beta peptides into / lateral and -1.75mm dorsal / ventral from Bregma).

<1-2> Effect of Camphor Extract on Gait Activity

When the camphor extract was administered to the Alzheimer's dementia animal model produced in Experimental Example 1-1, the following experiment was performed to observe motility and movement.

Specifically, the mouse was placed in a 50 × 50 × 50 ㎝ white acrylic box and the behavior was measured for 10 minutes using a video tracking system (video tracking system, smart v2.5.21). One week after the model induction of Alzheimer's dementia-induced mice, administration of Donepezil 1 mg / kg, Camphor leaf extract 200 mg / kg, 600 mg / kg or distilled water, which is a control group, spontaneously induced The amount of walking activity used was measured.

As a result, the animal model administered with distilled water after inducing Alzheimer's disease did not show a significant difference compared to the animal model that did not induce Alzheimer's disease. One). Through these results, it was confirmed that there is no problem in the motor function that can occur through drug administration, and the camphor leaf extract does not affect the walking activity amount.

< Experimental Example  2> Real time space of camphor extract Cognition  Confirm improvement

In order to evaluate the effect of short-term memory-type instantaneous spatial cognition improvement by camphor tree extract, 1 mg / kg of donepezil 1 mg / kg and camphor leaf extract 200 mg / kg after one week of model induction of the animal model produced in Experimental Example 1-1. Y-maze test was performed by administering 600 mg / kg or distilled water as a control group, respectively.

Specifically, the instrument used for the Y-shaped maze test is composed of three arms, each branch is 42 cm long, 3 cm wide, 12 cm high, and the angle at which the three branches are folded is 120 °. to be. All the experimental devices consisted of black polyvinyl plastic, and each branch was set to A, B, and C. The mouse was carefully placed on one branch and allowed to move freely for 8 minutes. Recorded. At this time, it was recognized as valid only when the tail was completely entered, and it was recorded even when the branch went back to the branch. In each case, three different branches (ABC, CAB, and BCA) were considered as actual alterations and given one point. Through this, the change behavioral force defined as going into all three in sequence was calculated, and was calculated by the following Equation 1.

[Equation 1]

Change Behavior Force (%)

= Actual alternation / maximum alternation × 100

(Highest change: total entries-2)

As a result, as shown in FIG. 2, it was confirmed that the altered behavioral force of the negative control group induced by the direct injection of amyloid beta peptides into the brain (1.2 μg / mouse, icv) was significantly decreased compared to the control group which was not injected ( 2). However, spontaneous alternation increased significantly compared to the negative control group. Increased voluntary change means that learning and memory have recovered. On the other hand, there was no change in the total entry, which indicates the total number of entry into each zone, indicating that spontaneous changes were not caused by changes in the activity of rats.

< Experimental Example  3> Confirmation of space learning and memory improvement effect of camphor extract

Passive avoidance tests were performed to evaluate spatial learning and memory by camphor extract.

Specifically, administration of the mouse animal model was performed in the same manner as in <Experimental Example 1-2>. The following experiment was carried out by applying the conventional method of Morris (Morris). First, the mice were transferred to the behavior observation room and stabilized 1 hour before the start of the experiment. Maze specifications are 90 cm in diameter, 32.5 cm in height, and the white platform is 5 cm in diameter. The periphery of the underwater maze kept the space cues always constant, such as computer systems and video thermostats connected to video cameras. The maze was then filled with water and placed under 1 cm of water height so that the mouse could not see the platform. The maze was divided into four quarters using four markers and divided into northeast (NE), northwest (NW), southeast (SE), and southwest (SW), and a platform was installed in one quadrant of the maze. The Morris water maze test was run for six days, and on the first day each mouse was allowed to swim freely in the maze for one minute to adapt to the water. From day 2 to day 5, each mouse was allowed to swim in the maze for 1 minute at 10 minute intervals, four times a day. In the first four days of the 5th day from the second day, a single test method will not find a platform within 1 minute after finishing the experiment, or 10 seconds on the platform if the mouse is already in the labyrinth for 10 seconds. After the end of the experiment, the mouse was artificially placed on the platform for 10 seconds and the experiment was terminated, and the position of the platform was fixed at the same position. On day 6, the platform was removed from the labyrinth and the time the mouse stayed in the garden where the platform was located was measured. In order to perform the memory test on the last day of the Morris Maze learning, the free swimming was performed for 60 seconds after the platform was removed and the time spent in the quadrant of the total time was measured by the Smart program. . The experimental group was treated with normal mouse control group not administered amyloid beta peptide and amyloid beta peptide injection negative control group, mice made with dementia animal model, positive control group with amyloid beta peptide and donepezil and 200, 600 It consisted of the experimental group injected with the camphor leaf extract of mg / kg.

As a result, as shown in FIG. 3 and Table 1, the control group was 67.97 ± 3.14481%, the negative control group administered with amyloid beta peptides was 38.56 ± 2.69489%, and the positive control group administered with amyloid beta peptides and donepezil was 60.4986 ± 4.35727. %, 59.5614 ± 3.235% of Experimental Group 1 administered 200 mg / kg of amyloid beta peptides and camphor leaf extract and 53.4714 ± 4.62295% of Experimental Group 2 administered 600 mg / kg of amyloid beta peptides and camphor leaf extract. There was a significant difference between the groups (Table 1).

group	Amyloid Beta Peptide Injection (Aβ infusion)	% Stay at target quadrant
Control	X	67.97 ± 3.14481
Negative Control	○	38.56 ± 2.69489 ###
Positive control group	○	60.4986 ± 4.35727 **
Experiment group 1	○	59.5614 ± 3.235 ***
Experiment group 2	○	53.4714 ± 4.62295 *

Each value was ^### p <0.001 compared to the mean SEM control, and * p <0.05 compared to the amyloid beta peptide injection group. ** p <0.005 and *** p <0.001 are shown.

Through these results, it was confirmed that camphor extract has an improvement and treatment effect of Alzheimer's dementia by confirming that camphor leaf extract can alleviate the decrease in learning and memory that can occur when Alzheimer's dementia is induced. .

Claims (8)

1. Camphor tree ( Cinnamomum camphora ) A pharmaceutical composition for the prevention and treatment of diseases of the nervous system, containing the extract as an active ingredient.
2. According to claim 1, wherein the camphor tree is a pharmaceutical composition for the prevention and treatment of diseases of the nervous system, characterized in that using the leaves.
3. According to claim 1, wherein the extract is a pharmaceutical composition for the prevention and treatment of diseases of the nervous system, characterized in that the extract is extracted with a solvent of water, C ₁ to C ₂ lower alcohol, or a mixture thereof.
4. According to claim 3, wherein the lower alcohol is ethanol or methanol pharmaceutical composition for the prevention and treatment of diseases of the nervous system, characterized in that
5. According to claim 1, wherein the neurological disease is spinal cord injury, Parkinson's disease (Parkinson's disease), stroke, amyotrophic spinal sclerosis, motor neuron injury, peripheral nerve injury due to trauma, ischemic brain injury, neonatal hypoxic ischemic brain injury, Cerebral palsy, epilepsy, intractable epilepsy, Alzheimer's disease, Alzheimer's disease, congenital metabolic neurological disease and traumatic brain injury, characterized in that any one selected from the group consisting of a pharmaceutical composition for the prevention and treatment of neurological diseases.
6. Health functional food for the prevention and improvement of neurological diseases containing camphor extract as an active ingredient.
7. According to claim 6, wherein the camphor tree is a functional food for the prevention and improvement of diseases of the nervous system, characterized in that using the leaves.
8. According to claim 6, wherein the neurological disease is spinal cord injury, Parkinson's disease (Parkinson's disease), stroke, amyotrophic spinal sclerosis, motor neuron injury, peripheral nerve injury due to trauma, ischemic brain injury, neonatal hypoxic ischemic brain injury, Cerebral palsy, epilepsy, intractable epilepsy, Alzheimer's disease, Alzheimer's disease, congenital metabolic neurological disease and traumatic brain injury, characterized in that any one selected from the group consisting of health functional foods for the prevention and improvement of neurological diseases.

Images